Shelly Bray, MD
Family Medicine · Arkadelphia, ARNPI 1902824162
Payments from drug & device makers
Across 266 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$735
- AstraZeneca$669
- Novo Nordisk$379
- Lilly USA, LLC$297
- Johnson & Johnson$240
- Pfizer$222
- plus $1K from 26 others
What the payments were for
- Food & beverage$4,00499%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 44 | $735 |
| AstraZeneca | 39 | $669 |
| Novo Nordisk | 29 | $379 |
| Lilly USA, LLC | 19 | $297 |
| Johnson & Johnson | 19 | $240 |
| Pfizer | 15 | $222 |
| AbbVie | 14 | $183 |
| Exact Sciences | 8 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $139 |
| Boehringer Ingelheim | 10 | $136 |
| GSK | 9 | $132 |
| Merck | 9 | $132 |
| Sanofi-aventis U.S. LLC | 5 | $63 |
| Dexcom, Inc. | 4 | $62 |
| Esperion Therapeutics, Inc. | 4 | $59 |
| Novartis | 4 | $55 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Abbott | 2 | $32 |
| Alkermes, Inc. | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $16 |
| Lundbeck LLC | 1 | $14 |
| Mylan Specialty L.p. | 1 | $12 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
How this compares
$4,028 in reported general payments places this provider in the 80th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 238 | $254,324 |
| TrulicityDulaglutide | 134 | $162,309 |
| EliquisApixaban | 219 | $153,890 |
| MounjaroTirzepatide | 113 | $136,154 |
| OzempicSemaglutide | 101 | $128,718 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 142 | $107,074 |
| FarxigaDapagliflozin Propanediol | 96 | $79,533 |
| Tresiba Flextouch U-200Insulin Degludec | 78 | $79,174 |
| OtezlaApremilast | 12 | $67,713 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $31,722 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $21,246 |
| VraylarCariprazine Hcl | 15 | $20,823 |
| Repatha SureclickEvolocumab | 25 | $19,439 |
| LinzessLinaclotide | 22 | $13,695 |
| QuliptaAtogepant | 12 | $12,593 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $297 | $298,463247 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat | $136 | $267,957262 claims |
| PfizerEliquis, Prempro | $222 | $156,834232 claims |
| Novo NordiskOzempic | $379 | $128,718101 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $132 | $118,622164 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $669 | $103,913137 claims |
| AmgenOtezla | $735 | $67,71312 claims |
| AbbVieVraylar, Linzess, Qulipta | $183 | $47,11049 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $63 | $31,72225 claims |
| Johnson & JohnsonInvokana | $240 | $7,78714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Arkadelphia
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
- Glenn GibbonsFort Smith$179K
- Christopher BrownJonesboro$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.